Literature DB >> 6487916

Smoking and malignancy in schizophrenia.

E Masterson, B O'Shea.   

Abstract

It has been suggested that schizophrenic patients have a lower risk of cancer than the general population. We therefore investigated the smoking patterns of 100 current chronic schizophrenic in-patients, and the causes of death in 122 recently deceased schizophrenics. We found that schizophrenics are heavy smokers, and that schizophrenics do die from carcinoma of the bronchus. Proportional mortality rates for all malignancies were not significantly lower in schizophrenics than in the general population but there was a significant absence of cancer of the gastro-intestinal tract. Proportional mortality rates for female mammary carcinoma, pneumonia, and suicide were raised, and that for cerebrovascular disease was low. These differences between schizophrenics and the general population warrant further investigation.

Entities:  

Mesh:

Year:  1984        PMID: 6487916     DOI: 10.1192/bjp.145.4.429

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  30 in total

1.  Neurodevelopmental liabilities of substance abuse.

Authors:  Tomas Palomo; Trevor Archer; Richard J Beninger; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2002-06       Impact factor: 3.911

Review 2.  Toward a smoke-free policy in mental health facilities.

Authors:  B L Levin; M D Knox
Journal:  J Ment Health Adm       Date:  1991

3.  Is initiation of smoking associated with the prodromal phase of schizophrenia?

Authors:  Kaisa Riala; Helinä Hakko; Matti Isohanni; Anneli Pouta; Pirkko Räsänen
Journal:  J Psychiatry Neurosci       Date:  2005-01       Impact factor: 6.186

Review 4.  Oxidative stress in schizophrenia: an integrated approach.

Authors:  Byron K Y Bitanihirwe; Tsung-Ung W Woo
Journal:  Neurosci Biobehav Rev       Date:  2010-10-23       Impact factor: 8.989

5.  The incidence of cancer in schizophrenic patients.

Authors:  P B Mortensen
Journal:  J Epidemiol Community Health       Date:  1989-03       Impact factor: 3.710

Review 6.  Cancer 'survivor-care': I. the α7 nAChR as potential target for chemotherapy-related cognitive impairment.

Authors:  R B Raffa
Journal:  J Clin Pharm Ther       Date:  2010-08-24       Impact factor: 2.512

Review 7.  Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Authors:  Ann Olincy; Karen E Stevens
Journal:  Biochem Pharmacol       Date:  2007-07-17       Impact factor: 5.858

Review 8.  Subtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: evidence from genetically modified mice.

Authors:  Christie D Fowler; Michael A Arends; Paul J Kenny
Journal:  Behav Pharmacol       Date:  2008-09       Impact factor: 2.293

9.  Health care of the chronically mentally ill: the culture broker model.

Authors:  B Schwab; R E Drake; E M Burghardt
Journal:  Community Ment Health J       Date:  1988

10.  A UK audit of screening for the metabolic side effects of antipsychotics in community patients.

Authors:  Thomas R E Barnes; Carol Paton; Mary-Rose Cavanagh; Elizabeth Hancock; David M Taylor
Journal:  Schizophr Bull       Date:  2007-05-04       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.